Literature DB >> 9531587

New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides.

L Lecomte-Raclet1, M Alemany, A Sequira-Le Grand, J Amiral, G Quentin, A M Vissac, J P Caen, Z C Han.   

Abstract

Platelet factor 4 (PF4) has been recognized as an inhibitor of myeloid progenitors. However, the mechanism of action of this chemokine remains poorly understood. The present study was designed to determine its structure/function relationship. A series of peptides overlapping the C-terminal and central regions of PF4 were analyzed in vitro for their action on murine hematopoietic progenitor growth to assess the minimal sequence length required for activity. The peptides p17-58 and p34-58 possessed an increased hematopoietic inhibitory activity when compared with PF4, whereas the shorter peptides p47-58 and p47-70 were equivalent to the native molecule and the peptide p58-70 was inactive. The PF4 functional motif DLQ located in 54-56 was required for the activity of these peptides. The peptide p34-58 impaired to a similar extent the growth of colony-forming unit-megakaryocyte (CFU-MK) as well as burst-forming unit-erythroid (BFU-E) and colony-forming unit-granulocyte-macrophage (CFU-GM), whereas PF4 was more active on CFU-MK. In the experiments using purified murine CD34(+) marrow cells, statistically significant inhibition induced by p34-58 was shown at concentrations of 2.2 nmol/L or greater for progenitors of the three lineages, whereas that induced by PF4 was seen at 130 nmol/L for CFU-MK and 650 nmol/L for CFU-GM and BFU-E, indicating that the p34-58 acts directly on hematopoietic progenitors and its activity is approximately 60- to 300-fold higher than PF4. The p34-58, unlike PF4, lacked affinity for heparin and its inhibitory activity could not be abrogated by the addition of heparin. In addition, an antibody recognizing p34-58 neutralized the activity of p34-58 but not whole PF4 molecule. These results demonstrate that PF4 contains a functional domain in its central region, which is independent of the heparin binding properties, and provide evidence for a model of heparin-dependent and independent pathways of PF4 in inhibiting hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531587

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Megakaryocytes regulate the quiescence of hematopoietic stem cells through PF4: 2013 ASH meeting highlights.

Authors:  Yamei Chen; Delong Liu
Journal:  Stem Cell Investig       Date:  2014-04-02

2.  Generation and Characterization of a New Monoclonal Antibody Against CXCL4.

Authors:  Jing Gao; Mingyuan Wu; Jin Gao; Xia Wang; Yang Zhang; Shunying Zhu; Yan Yu; Wei Han
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-04

Review 3.  Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.

Authors:  Katerina Pilatova; Kristina Greplova; Regina Demlova; Beatrix Bencsikova; Giannoula Lakka Klement; Lenka Zdrazilova-Dubska
Journal:  J Hematol Oncol       Date:  2013-06-24       Impact factor: 17.388

4.  Saponins from Sanguisorba officinalis Improve Hematopoiesis by Promoting Survival through FAK and Erk1/2 Activation and Modulating Cytokine Production in Bone Marrow.

Authors:  Xin Chen; Bogang Li; Yue Gao; Jianxin Ji; Zhongliu Wu; Shuang Chen
Journal:  Front Pharmacol       Date:  2017-03-16       Impact factor: 5.810

5.  An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.

Authors:  Laura Lasagni; Michela Francalanci; Francesco Annunziato; Elena Lazzeri; Stefano Giannini; Lorenzo Cosmi; Costanza Sagrinati; Benedetta Mazzinghi; Claudio Orlando; Enrico Maggi; Fabio Marra; Sergio Romagnani; Mario Serio; Paola Romagnani
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

6.  Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.

Authors:  Aleksandra Sobolewska; Marcin Włodarczyk; Krystyna Stec-Michalska; Jakub Fichna; Maria Wiśniewska-Jarosińska
Journal:  Dig Dis Sci       Date:  2015-10-06       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.